Ruzasvir
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Ruzasvir
- Molecular weight
- 947.11
- Structure (SMILES)
- COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2cc(F)c3c(c2)O[C@@H](c2cnc(C4CC4)s2)n2c-3cc3cc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)ccc32)[nH]1)C(C)C
- mk 8408
- MK-8408
- ruzasvir
- Ruzasvir
- ruzasvir [INN]
- RUZASVIR [USAN]
- Ruzasvir [WHO-DD]
- Ruzasvir 60 mg
- ruzasvir inn
- ruzasvir usan
- ruzasvir who dd
- CAS registry numbers
- 1613081-64-3
- ChEMBL ID
- CHEMBL3971095
- InChIKey
- AXWDHVUJXNOWCC-RAEGKSCOSA-N
- PubChem compound IDs
- 91936863
- FDA ingredient codes (UNII)
- LX752BD95Y
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -vir
Mechanisms of action
- Mechanism
- Nonstructural protein 5A inhibitor
- Action type
- Inhibitor
- Target
- Nonstructural protein 5A
- Protein identifier
- Q5L478
Open Targets mechanisms
- Mechanism
- Nonstructural protein 5A inhibitor
- Action type
- Inhibitor
- Target
- Nonstructural protein 5A
- Condition
- Hepatitis C
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003047
- Subject identifier
- D006526
- Condition
- Hepatitis C, Chronic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004220
- Subject identifier
- D019698
- Condition identifier
- EFO_0003047
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005231
- Highest recorded phase
- 3
- NCT02076100
- NCT02332707
- NCT02332720
- NCT02956629
- NCT02666352
- NCT02759315
- Hydrogen bond acceptors
- 12
- Hydrogen bond donors
- 4
- Polar surface area
- 201.69
- Calculated partition coefficient (ALogP)
- 8.59
- Calculated partition coefficient (XLogP)
- 6.4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 3
- Rotatable bonds
- 12
- Heavy atoms
- 68
- Molecular formula
- C49H55FN10O7S
- Monoisotopic mass
- 946.39599347
- Natural product
- No
- Recorded assays
- 30
- Active assays
- 17
Active assay types
- Confirmatory
- Antiviral Agents
Oral bioavailability
- Median
- 13
- Mean
- 13
- Minimum
- 4
- Maximum
- 22
- Unit
- %
- Assays
- 2
- Standard deviation
- 12.7279
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (13)
- A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
- A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
- Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir
- Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir
- Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
- Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)
- Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)
- Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir
- Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)
- Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
In development for (2)
- Chronic hepatitis C virus infection Phase 2
- Hepatitis C virus infection Phase 2